A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Type 1 Diabetes MellitusType 2 Diabetes Mellitus
- Interventions
- Drug: US-Lantus
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Lannett Company, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT05248841
- Locations
- 🇿🇦
FARMOVS Clinical Research Organization, Bloemfontein, Free State, South Africa
Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
Phase 3
Completed
- Conditions
- Any Ear Nose or Throat ConditionsWith Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
- Interventions
- Drug: Placebo Topical Solution
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Lannett Company, Inc.
- Target Recruit Count
- 646
- Registration Number
- NCT02500836
- Locations
- 🇺🇸
Richmond ENT, Richmond, Virginia, United States
Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia
Phase 3
Terminated
- Conditions
- Procedures and Surgeries on or Through Accessible Mucous Membranesof the Nasal CavitiesDiagnostic
- Interventions
- Drug: Placebo Topical Solution
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Lannett Company, Inc.
- Target Recruit Count
- 159
- Registration Number
- NCT01746940
- Locations
- 🇺🇸
The Connecticut Sinus Center, PC, Bridgeport, Connecticut, United States
🇺🇸Research Across America, Plano, Texas, United States